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Abstract
We have previously hypothesized a biological pathway of activity-dependent synaptic plas-
ticity proteins that addresses the dual genetic and environmental contributions to schizo-
phrenia. Accordingly, variations in the immediate early gene EGR3, and its target ARC,
should influence schizophrenia susceptibility. We used a pooled Next-Generation Sequenc-
ing approach to identify variants across these genes in U.S. populations of European (EU)
and African (AA) descent. Three EGR3 and one ARC SNP were selected and genotyped for
validation, and three SNPs were tested for association in a replication cohort. In the EU
group of 386 schizophrenia cases and 150 controls EGR3 SNP rs1877670 and ARC SNP
rs35900184 showed significant associations (p = 0.0078 and p = 0.0275, respectively).
In the AA group of 185 cases and 50 controls, only the ARC SNP revealed significant asso-
ciation (p = 0.0448). The ARC SNP did not show association in the Han Chinese (CH) popu-
lation. However, combining the EU, AA, and CH groups revealed a highly significant
association of ARC SNP rs35900184 (p = 2.353 x 10−7; OR [95% CI] = 1.54 [1.310–1.820]).
These findings support previously reported associations between EGR3 and schizophrenia.
Moreover, this is the first report associating an ARC SNP with schizophrenia and supports
recent large-scale GWAS findings implicating the ARC complex in schizophrenia risk.
These results support the need for further investigation of the proposed pathway of environ-
mentally responsive, synaptic plasticity-related, schizophrenia genes.
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Introduction
Schizophrenia is a severe mental illness that affects approximately 1% of the world’s population
and is determined by both genetic and environmental factors [1, 2]. The genetic contribution
to schizophrenia risk ranges from 50–80% [1, 3]. The remaining influence may be attributed to
environmental factors [2]. However, how environmental exposures interact with genetic varia-
tions to influence schizophrenia susceptibility remains unclear.
Immediate early gene (IEG) transcription factors are rapidly activated in the brain in
response to environmental stimuli and regulate downstream neuronal gene expression. The
early growth response gene (EGR) family of IEG transcription factors is involved in numerous
neural processes, including regulation of synaptic proteins and synaptic plasticity, dysfunction
of which have been hypothesized to play a role in schizophrenia pathogenesis [4–10].
Numerous findings suggest a role for the IEG EGR3 in schizophrenia susceptibility. Single
nucleotide polymorphisms (SNPs) in EGR3 are associated with schizophrenia in Japanese,
Korean, and Han Chinese (CH) populations [11–13], and levels of EGR3mRNA are reduced
in post-mortem brain tissue from schizophrenia patients [11, 14]. We have previously reported
that Egr3-deficient (Egr3KO) mice display schizophrenia-like behavioral abnormalities that are
reversible with antipsychotic treatment [4, 15]. EGR3 is regulated downstream of several key
schizophrenia candidate proteins, including Neuregulin 1, N-methyl D-Aspartate Receptors
(NMDARs) and calcineurin (CN) [11, 16–21], and Egr3KOmice share key phenotypes with
NMDARKO and CNKO mice, including memory dysfunction and deficits in the form of hip-
pocampal synaptic plasticity long-term depression (LTD) [4, 22, 23]. These shared characteris-
tics suggested to us that these proteins may form a biological pathway of genes which, when
disrupted may increase risk for schizophrenia. If so, then dysfunction of the gene activity-regu-
lated cytoskeleton-associated protein (ARC) [24], which is a downstream target of EGR3 and is
similarly required for memory formation and hippocampal LTD in mice [25–27], may also
confer risk for schizophrenia.
In support of this hypothesis, several large-scale studies have identified associations between
schizophrenia and genes whose proteins complex with ARC in the post-synaptic density of
neurons [28–30]. However, to date there have been no reports of genetic association between
SNPs in the ARC gene itself and schizophrenia. In addition, significant associations between
SNPs in EGR3 and schizophrenia have not been reported in populations of European or Afri-
can descent. We therefore carried out the current studies to test the hypothesis that EGR3 and
ARC are schizophrenia risk associated genes.
Materials and Methods
DNA Samples
DNAs from EU and AA patients diagnosed with schizophrenia based on DSM-IV classification
were obtained from the National Institute of Mental Health Schizophrenia Genetics Initiative
(NIMH-SGI) Release 1.0 and Release 3.0. Control samples were obtained from the NIMH-GI
Control Database Release 3.0 and the Environmental Catchment Area ADHD Study. Addi-
tional control genotypes were obtained from the 1,000 genomes published findings [31]. Writ-
ten informed consent was obtained from subjects in all studies. These samples were obtained
in a de-identified manner and were thus exempt from approval by the University of Arizona
Institutional Review Board (IRB).
The study involving CH samples was approved by the genetic research ethics committee
(equivalent to the IRB) of Xi’an Jiaotong University School of Medicine and written informed
consent was obtained from all subjects. A total of 982 subjects included 491 schizophrenics
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(253 males, mean age = 34.49±11.85, age of onset = 24.30±7.22; 238 females, mean age = 31.77
±13.50, age of onset = 24.42±8.64) and 491 normal controls (272 males, mean age = 28.92
±13.78; 219 females, mean age = 28.88±13.83). All patients were diagnosed by the psychiatrists
of the First Affiliated Hospital of Xi’an Jiaotong University School of Medicine according to
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for schizophrenia
using a combination of examination of psychiatric case records and clinical interview. The
diagnosis was checked and verified by two independent senior psychiatrists who reviewed the
psychiatric case records.
CH controls were drawn from a combination of local volunteers or blood transfusion
donors. Subjects with current or past evidence of mental illness, or with a first-degree relative
with mental illness, were not included in the cohort. In addition, in China only healthy people
not taking medication can donate blood, hence the evaluated controls were medication-free.
Overall, these controls are unlikely to include a significant number of psychotic individuals, if
indeed any. All subjects were Han Chinese in origin and from Northwest China.
Next-Generation Sequencing (NGS)
Amplification and sample preparation. Pooled DNA samples were PCR amplified using
RainStorm (RainDance Technologies, Inc. Billerica, MA) essentially as described in [32].
Briefly, individual DNA samples were quantitated in triplicate with PicoGreen reagent (Life
Technologies, Grand Island, NY) and equimolar pools were created based on sex, race, and
diagnosis. Individual DNAs were fragmented to 2–4 kb lengths and merged with a panel of
primers designed to create overlapping amplicons spanning the entire coding and noncoding
sequence of EGR3 and ARC, from 7 Kb upstream of the 5’UTR to 3 Kb downstream of the
3’UTR. See S1 Table for primer sequences. RainStorm PCR was performed and amplification
products were concatenated using the New England Biolabs (NEB) Quick blunting and ligation
kit (Ipswich, MA).
Amplicons were sonicated for 2.5 minutes to produce 100–400 bp DNA fragments, treated
with Klenow enzyme Fragment for 30 minutes, blunt-ended with T4 DNA polymerase and T4
polynucleotide kinase, and purified using the Ampure SPRI bead purification system (Beck-
man Coulter, CA). Fragments were 3’ end-labeled with an untemplated A base (Klenow 3’-5’
exo- and dATP for 30’) followed by Ampure purification and PicoGreen quantification (Invi-
trogen, Inc., NY). NGS universal adapters were modified with unique DNA bar-codes as previ-
ously described [33]. Ligation was performed using 10:1 molar ratio of bar-coded adapters:
DNA fragments using high concentration T4 DNA ligase for 15’. The ligation product under-
went gel purification (run on a 3% agarose gel at 100 v for 2 h, the 300 bp band was excised and
purified using Freeze’ N Squeeze (Bio-Rad Laboratories, Inc., CA) columns) and PCR amplifi-
cation. A second round of gel purification isolated the 200bp-350bp fragment to form a DNA
library bar-coded for each individual DNA sample.
NGS of pooled bar-coded DNAs. Individual bar-coded DNA libraries were combined
into pools and added to a sequencing flowcell to generate clusters that were subjected to NGS.
The molecular bar-coding approach facilitated sequencing of DNA samples from multiple
pools on each lane of the flowcell.
NGS data analysis and variant detection. Data from the Illumina Genome Analyzer was
converted to text-based sequence with the Illumina Pipeline 1.4 and CASAVA 1.0 software
using standard Illumina protocols. Image cluster identification, sharpening, background sub-
traction, and intensity extraction were performed with the Firecrest module. Base calling and
phasing/prephasing effects were corrected for using the Bustard module. Using the pass/fail fil-
ter generated by Bustard, Sanger Phred-33 FASTQ files were created with a custom perl script
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in preparation for alignment. FASTQ format was chosen because each sequence read is
described with the sequence and individual base quality scores, metadata from the instrument,
cluster position and paired-read info, and many of the commonly used aligners use the FASTQ
format.
NGS data were aligned with the reference genome using the BWA aligner [34], the tool used
by the 1000 Genomes project, which uses SAM (Sequence Alignment/Map) format [35]. The
SAM format contains information on mapping quality, mapping coordinates, mismatches, and
fields for user specified metadata. BWA alignment was carried out using default modes for 36
bp single and paired read (72 bp total) runs. Reads were mapped to the reference human
genome used by the 1000 Genomes project [31]. After alignment, variants were called with
`VarScan.v2.2.jar pileup2snp`with the options `—min-coverage 250—min-reads2 10—min-
avg-qual 20—min-var-freq 0.02—p-value 0.01`.
Genotyping of selected SNPs
DNA samples from the NGS discovery cohort were genotyped for three EGR3 SNPs and one
ARC SNP for the validation phase association analyses. Additional schizophrenia case DNAs
for the replication association study were obtained from NIMH-SGI release 3.0. DNAs, were
quantitated by nanodrop spectrophotometry, diluted in sterile Tris buffer, 10mM, pH 7.4, to a
concentration of 4 ng/ul, and confirmed using PicoGreen (Invitrogen, Inc., NY) quantification,
according to the manufacturer’s protocol. Samples were plated on to 96 well plates at 20 ng/
well, and dried down overnight at room temperature in the dark. DNAs were genotyped using
individual SNP assays from Applied Biosystems Inc., (ABI, Foster City, CA) on an ABI 7500
Fast QRT-PCR instrument following the manufacturer’s protocol.
Genotyping of CH samples was performed using direct DNA sequence analysis. The PCR
primers for amplification of the rs35900184 were as follows: forward primer 5’- CGCCTGGA
GAAGAATCAGAG-3’ and reverse primer 5’- AAAGACTTTGTGGGAACCTTGA-3’. The
PCR reaction was performed in 25 μl of standard PCR buffer containing 1.5mMMgCl2,
0.2mM of each dNTP, 0.5μl of each primer, 1 unit of Taq DNA polymerase, and 25 ng of
human genomic DNA. The program was one cycle of 2min for denaturation at 95°C, 35 cycles
of 30s at °C, 35s at 58°C, 45s at 72°C, and one 7min extension step at 72°C. Purified PCR prod-
ucts were sequenced bi-directionally using PCR primers as sequencing primers and the
Applied Biosystems Prism BigDye terminator cycle sequencing reaction kit. The products were
evaluated on an ABI 3730 Genetic Analyzer (Applied Biosystems).
Individual Genotype Analysis
Genotype data were analyzed using PLINK v1.07 [36], and the Fisher test with 95% confidence
intervals.
Linkage Disequilibrium (LD) Analyses
Haploview [37] was used to estimate LD between SNPs across the ARC region in the CEPH
population (Utah residents with ancestry from northern and western Europe, abbreviated
CEU), Hapmap [38] data release 28. The ARC region (chromosome 8, from 143,689,412 to
143,692,835) included 18 SNPs in the CEU Hapmap individuals. Hapmap Genome Browser
release 28 (http://hapmap.ncbi.nlm.nih.gov/) with Copy Number Variation Region Track
enabled, was used to identify known CNVs in the ARC region on chromosome 8.
EGR3 and ARC Associations with Schizophrenia
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Power Analyses
Calculating power for genetic studies requires knowledge of values such as the prevalence of
the disease, the relative risk of the disease risk allele (the ratio of the probability of disease
occurrence in the risk-allele carriers to the probability of disease occurrence in individuals that
are not carriers of the risk-allele) and the frequency of the disease allele. Since these parameters
are unknown for the current study, estimates were used, and the disease risk allele was assumed
to be included in our sample. Assuming values of 0.01 for disease prevalence, relative-risk of
1.5 (a relatively optimistic value for a complex disease such as schizophrenia), alpha-level of
0.05 and a standard 1df allelic test, then the estimated power to detect a significant association
ranges from 0.05 to 0.47 (for disease allele frequencies ranging from 0.1 to 0.9) for a sample
size of 386 cases and 150 controls, as was our EU cohort. For our AA cohort (sample size of
185 and 50 controls) the power range is lower, from 0.05 to 0.21 only. These parameter ranges
indicate that our sample size of fewer than 200 cases and 50 controls is underpowered to detect
an association in the SNPs in the AA cohort, should one truly exist. Increasing the number of
cases and controls to N = 1,200, and 300, respectively, would increase the power to detect a
positive association to 0.80, for disease allele frequencies of 0.2 (which approximates the MAF
for rs1877670 in AA). The Genetic Power Calculator was used to generate these power esti-
mates [39].
Results
Since the frequencies of specific SNPs, as well as their potential association with an illness, vary
among ethic and racial groups, it can be difficult to select the SNPs that have a high likelihood
of showing association within the population of study. In studies with limited sample sizes lim-
iting the number of SNPs queried helps to maintain statistical power. To address these issues
we employed a method using NGS to identify all variations across the EGR3 and ARC loci
from a discovery cohort of pooled DNA samples. SNPs in which one allele demonstrates a high
degree of difference in frequency between cases and controls, particularly in two separate popu-
lations, may be more likely to show association with illness.
NGS of the EGR3 and ARC loci
To identify variations within the EGR3 and ARC loci that have a high likelihood for association
with schizophrenia risk in two different racial groups, we used a two-step approach. For the ini-
tial step we used a “Discovery” cohort of DNA samples from schizophrenia patients (cases)
and non-psychiatrically ill individuals (controls) that were matched for sex and race (EU and
AA). Table 1 shows how these samples were pooled into 16 groups of up to 25 samples per
group. NGS across the EGR3 and ARC loci was performed on each pool and results were com-
pared among pools for quality control.
Allele frequencies were estimated for each variant along the entire sequenced region in each
pooled group using CRISP [40]. The results were averaged among pools according to case/con-
trol status and race (sex was not maintained as a variable). For each variant the difference in
the average frequency of the minor allele between cases and controls, termed the “delta Minor
Allele Frequency” (ΔMAF), was calculated by subtracting the average MAF for schizophrenia
patients from that for controls of the same race. S2 and S3 Tables show the allele frequency
results for all variations identified in the EGR3 region, ranked from highest to lowest ΔMAF,
in the EU and AA groups. S4 and S5 Tables show the same analysis for the sequenced ARC
region in the respective EU and AA groups.
The ΔMAF results for the sequenced regions of the EU (in blue) and AA (in red) popula-
tions were plotted onto the genome map in the regions of EGR3 (Fig 1A) and ARC (Fig 1B)
EGR3 and ARC Associations with Schizophrenia
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Table 1. Characteristics of DNA Pools Used for Next Generation Sequencing.
Race Sex Affected Status No. of Subjects/Pool No. of Pools Total No. of Subjects
EU F Cases 25 2 50
F Controls 25 2 50
M Cases 23–25 4 95
M Controls 25 4 100
AA F Cases 18 1 18
F Controls 25 1 25
M Cases 24 1 24
M Controls 25 1 25
doi:10.1371/journal.pone.0135076.t001
Fig 1. Minor Allele Frequency Differences in EU and AA.Results of polymorphisms identified by NGS are mapped to the reference human genome used
by the 1000 Genomes project (hg18). Vertical lines indicate the ΔMAF (difference between the minor allele frequency in cases versus controls) for each base
pair of the genome region investigated. Higher peaks indicate a greater difference in prevalence of that variation between cases and controls, and thus a
higher potential for association with schizophrenia risk. The red graph indicates data for Whites and the Blue graph indicates data for African Americans. (A)
ΔMAFmap for the EGR3 locus, hg18 coordinates chr8:22,591,791–22,612,066. (B) ΔMAFmap for the ARC locus, hg18 coordinates chr8:143,682,474–
143,697,026
doi:10.1371/journal.pone.0135076.g001
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using the UCSC genome browser. Individual variations that produced high peaks (i.e. greater Δ
MAF) in both racial groups were of greatest interest.
Case-Control Genetic Association Analyses
Several SNPs were selected for validation of the NGS results by genotyping of the individual
DNA samples from the discovery cohort. Variations for genotyping validation were selected
based on a combination of criteria, including high ΔMAF values in both race cohorts and/or
having been reported as associated with schizophrenia in other populations. Three SNPs from
the EGR3 region were selected. The SNP rs1877670 displayed the highest ΔMAFs in our EU
cohort, and ranked eighth in the AA cohort, with a ΔMAF of 7.0%. This SNP was also reported
in a haplotype associated with schizophrenia in a CH population [41]. rs1996147 demon-
strated ΔMAFs of 8.6% in EUs and 5.9% in AAs in our NGS discovery analysis, and showed
nominally significant association with bipolar disorder in a study of circadian rhythm genes
[42]. The SNP rs10095121 showed a ΔMAFs of 2.9% in EUs and 8.4% in AAs in our NGS
results, and revealed nominally significant association with the diagnosis of child bipolar I dis-
order in our prior family based association study [43].
Since no studies had been published investigating ARC SNPs for association with schizo-
phrenia, selection of a single ARC SNP was made based only on high ΔMAF values in both
race cohorts. The SNP rs28420666 was initially selected for genotyping as it demonstrated Δ
MAF of 24.8% in the EU cohort 8.3% in the AA cohort. However our attempts to create a geno-
typing assay for this SNP were unsuccessful. Therefore SNP rs35900184, which showed Δ
MAFs of 10.2% in EUs and 6.6% in AAs, was selected.
Tables 2 and 3 show the results of the validation phase. Of note, the pooled sequencing
approach yielded MAFs that were similar to the confirmed individual-based results (e.g. com-
paring MAF Controls versus MAF Pooled Controls columns in Tables 2 and 3). In the EU
group EGR3 SNP rs1877670 showed a trend toward association (p = 0.07), and the ARC SNP
rs35900184 revealed a significant association with the schizophrenia diagnosis (p = 0.02). In
the AA cohort, there were no significant associations between the three EGR3 or the single
ARC SNP tested, though the ARC SNP rs1996147 showed a trend toward significance
(p = 0.07). We selected the three SNPs that showed significance or trended toward significance
for further evaluation in a replication group.
A replication cohort was generated by inclusion of additional cases to the samples from the
discovery cohort. No additional controls were included due to lack of availability. The results
of association analyses for the two EGR3 and one ARC SNP genotyped for the replication
cohort are shown in Tables 4 and 5. In the EU replication study EGR3 SNP rs1877670 showed
a significant association with schizophrenia (p = 0.0078). The ARC SNP rs35900184 main-
tained a significant association with the schizophrenia diagnosis (p = 0.0275) in the replication
study. In the AA cohort only the ARC SNP rs35900184 demonstrated significance (p = 0.045).
An additional investigation of “Population Controls” from the publicly available 1,000
genomes data was performed [31]. This demonstrated the allele frequency of the four SNPs of
interest in presumed controls denoted as “GMAF” in Tables 2–8. These data show that the popu-
lation controls are in approximately the same allele frequency range as the clinical controls, sug-
gesting that these variants are indeed significantly enriched in the white schizophrenia cases.
ARC Association Study Han Chinese Sample
To test our hypothesis that ARC, a direct gene target of EGR3, is also a schizophrenia risk gene,
we genotyped rs35900184 in a CH population of 491 cases and 491 controls in which EGR3
had previously demonstrated association with schizophrenia [13]. Table 6 shows that the
EGR3 and ARC Associations with Schizophrenia
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minor allele of rs35900184 showed no significant difference in frequency between cases and
controls (p = 0.293) in this CH cohort.
Combined analysis of ARC and EGR3
To increase power and to investigate the role of our candidate variants independent of ethnicity
we performed a combined analysis of the SNPs (Tables 7 and 8). The EGR3 SNPs were not sig-
nificant in the combined group of EU and AA samples (the CH samples were not included as
EGR3 has previously been investigated for associations in this group [13]). However, the ARC
SNP, rs35900184, was significantly associated with schizophrenia in the combined group of
EU, AA, and CH samples (p = 2.5X10-7), with a suggested odds ratio of 1.54 (95% confidence
interval = 1.31–1.82) (Table 8). We also assessed the heterogeneity of our three candidate SNPs
across the study populations using a Breslow-Day test. The results of this indicated significant
heterogeneity at SNPs rs1877670 (p = 0.024) and rs35900184 (p = 4.5X10-3)(see S6 Table). To
address any potential confounds from this heterogeneity we performed a meta-analysis using a
random effects model in PLINK (see S7 Table). This resulted in a significant association noted
in the ARC SNP only (rs35900184, p = 1.9X10-4).
Variations in the ARC Region
A 30 Kb region of chromosome 8 spanning the ARC locus was interrogated using HapMap and
NCBI dbSNP resources to identify known SNPs and analyze LD in this region. (A similar
Table 2. Validation Phase: Comparison of Pooled Sample NGS with Individual Genotyping Results and Genetic Association Analyses in EU
cohort. Pooled EU.
SNP Chr Hg18
Position
A1 A2 MAF
Controls
MAF
Cases
MAF Pooled
Controls
MAF Pooled
Cases
GMAF P-
value
OR [95% CI]
rs10095121 8 22,538,426 C T 33.6% 32.8% 32.6% 29.8% 28.4% 0.8566 0.970 [0.680–
1.380]
rs1877670 8 22,546,561 C T 45.8% 54.1% 42.3% 47.6% 44.3% 0.0685 1.390 [0.990–
1.960]
rs1996147 8 22,544,158 G A 35.5% 32.7% 33.5% 25.0% 41.2% 0.5307 0.890 [0.620–
1.260]
rs35900184 8 143,693,411 T C 22.9% 32.3% 18.0% 28.1% 26.5% 0.0215 1.610 [1.090–
2.390]
145 cases, 150 controls; 195 males, 100 females.
doi:10.1371/journal.pone.0135076.t002
Table 3. Validation Phase: Comparison of Pooled Sample NGS with Individual Genotyping Results and Genetic Association Analyses in AA
cohort. Pooled AA.
SNP Chr Hg18
Position
A1 A2 MAF
Controls
MAF
Cases
MAF Pooled
Controls
MAF Pooled
Cases
GMAF P-
value
OR [95% CI]
rs10095121 8 22,538,426 C T 26.1% 24.4% 31.8% 20.0% 28.4% 0.8621 0.910 [0.460–
1.820]
rs1877670 8 22,546,561 C T 22.3% 14.6% 29.0% 19.0% 44.3% 0.2459 0.600 [0.270–
1.300]
rs1996147 8 22,544,158 G A 29.3% 17.1% 22.6% 15.3% 41.2% 0.0734 0.500 [0.240–
1.030]
rs35900184 8 143,693,411 T C 31.9% 41.2% 25.1% 34.0% 26.5% 0.2101 1.500 [0.800–
2.790]
42 cases, 50 controls; 49 males, 43 females.
doi:10.1371/journal.pone.0135076.t003
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analysis of the EGR3 region has previously been published [43].) The ARC SNP rs35900184 is
not included in either of these public resources. The HapMap project includes 18 SNPs in this
region, which have been genotyped in 11 populations (S1A Fig). Genotype data from the
CEPH population (Utah residents with ancestry from northern and western Europe, abbrevi-
ated CEU) was used to create a linkage disequilibrium map in Haploview, which revealed one
haplotype block in this region (S1B Fig). The ARC SNP rs35900184 is located outside of the
haplotype block in a region that is poorly genotyped in HapMap. Analysis of copy number var-
iation (CNV) domains revealed that ARC resides within a CNV region (S1C Fig).
Discussion
While numerous studies have identified candidate genes and genomic variations linked to risk
for psychiatric illnesses, few of them provide an explanation for the role of environment. We
have previously proposed that proteins acting in a biological cascade required for memory for-
mation and hippocampal LTD, comprise a pathway that, when disrupted, increases risk for
schizophrenia [4, 15, 44]. This pathway, triggered by activity-dependent opening of NMDARs,
allows neuronal calcium influx, which acts on CN, a Ca++ activated phosphatase, to activate
expression of the IEG transcription factor EGR3 [19, 21]. The gene ARC is a direct target of
EGR3 protein [24], and is also required for memory formation and LTD [4]. We therefore
hypothesized that, like the preceding proteins in this putative pathway, which have each been
implicated in schizophrenia risk, ARC should also be a schizophrenia susceptibility gene. Such
a collection of risk genes into one functional pathway can address both the polygenic nature of,
and environmental contribution to, schizophrenia risk.
In the current study we asked the whether genomic variations in the environmentally-acti-
vated IEGs EGR3 and ARC are associated with schizophrenia in two racial populations, EU
Table 4. Replication Phase: Genetic Association Between Schizophrenia and SNPs in EGR3 and ARC in EU Population. Replication EU.
SNP Chr Hg18
Position
A1 A2 MAF
Controls
MAF
Cases
MAF Pooled
Controls
MAF Pooled
Cases
GMAF P-
value
OR [95% CI]
rs1877670 8 22,546,561 C T 45.8% 55.6% 42.3% 47.6% 44.3% 0.0078 1.480 [1.110–
1.960]
rs1996147 8 22,544,158 G A 35.5% 32.5% 33.5% 25.0% 41.2% 0.3745 0.880 [0.660–
1.170]
rs35900184 8 143,693,411 T C 22.9% 30.0% 18.0% 28.1% 26.5% 0.0275 1.450 [1.050–
2.00]
386 cases, 150 controls; 363 males, 173 females.
doi:10.1371/journal.pone.0135076.t004
Table 5. Replication Phase: Genetic Association Between Schizophrenia and SNPs in EGR3 and ARC in AA Population. Replication AA.
SNP Chr Hg18
Position
A1 A2 MAF
Controls
MAF
Cases
MAF Pooled
Controls
MAF Pooled
Cases
GMAF P-
value
OR [95% CI]
rs1877670 8 22,546,561 C T 22.3% 20.5% 29.0% 19.0% 44.3% 0.6716 0.900 [0.520–
1.550]
rs1996147 8 22,544,158 G A 29.3% 25.1% 22.6% 15.3% 41.2% 0.4251 0.810 [0.490–
1.340]
rs35900184 8 143,693,411 T C 31.9% 43.7% 25.1% 34.0% 26.5% 0.0448 1.650 [1.020–
2.680]
185 cases, 50 controls; 127 males, 108 females.
doi:10.1371/journal.pone.0135076.t005
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and AA. We used NGS to comprehensively evaluate the frequency of variations present at the
EGR3 and ARC loci in both cases and controls. This allowed identification of multiple types of
polymorphisms, including rare variants, providing a much greater depth of investigation than
a classical SNP genotyping approach, which is limited to detection of SNPs occurring at>10%
frequency in the population. We hypothesized that this would be a more effective way to select
variations for genotyping than choosing known SNPs randomly across the genomic region for
an association study. It also allowed rapid and broad comparison of variation frequencies
among racial populations. We indicate the concordance in MAF of our candidate variants in
Tables 2 and 3. This demonstrates that the pooled sequencing approach is highly comparable
to the results obtained on the same individuals via genotyping.
Our major findings were that EGR3 SNP rs1877670 was associated with schizophrenia in
our population of EU cases and controls (p = 0.0078; Table 4). And the ARC SNP rs35900184
displayed association with schizophrenia risk in both the EU and the AA populations
(p = 0.0275 and p = 0.0448, respectively; Tables 4 and 5). Further, although ARC SNP
rs35900184 did not show statistically significant association with schizophrenia in the CH pop-
ulation alone (Table 6), when all three racial groups were combined to increase statistical
power, rs35900184 revealed a strongly significant association with schizophrenia (p = 2.353 x
10−7; OR [95% CI] = 1.54 [1.310–1.820]; Table 8). These findings support our hypothesis of a
biological pathway involving memory, hippocampal LTD, and schizophrenia susceptibility [4,
15, 44], by demonstrating that ARC, the downstream target of proteins in the pathway that are
associated with risk for schizophrenia, is itself associated with risk for this illness.
To our knowledge, this is the first study examining association between a SNP in ARC and
schizophrenia. It is also the first study reporting associations between SNPs in EGR3 and
schizophrenia in an AA population. Recent high-profile studies of rare copy number variations
(CNVs) and de novo variations enriched in schizophrenia patients have identified the impor-
tance of proteins that complex with ARC protein in the post-synaptic density in the risk for
schizophrenia [28–30, 45]. Small de novomutations in genes encoding proteins that associate
with ARC are overrepresented in schizophrenia patients versus controls [30]. And exome
sequencing has identified rare disruptive mutations involving proteins that associate with ARC
are more prevalent in schizophrenia patients than controls [29]. However, these large-scale
genome-wide studies did not identify associated variations in the ARC gene itself. Notably,
some of these were exome studies, so would not have included the regulatory region in which
the ARC SNP rs35900184 resides.
Table 6. Replication of ARC SNP Association with Schizophrenia in Han Chinese Population. Replication CH ARC.
SNP Chr Hg18 Position A1 A2 MAF Controls MAF Cases GMAF P-value OR [95% CI]
rs35900184 8 143,693,411 T C 17.3% 19.2% 26.5% 0.2933 1.140 [0.910–1.430]
491 cases, 491 controls; 525 males, 457 females.
doi:10.1371/journal.pone.0135076.t006
Table 7. EGR3 SNP Association Analyses in All Populations Combined. All Samples Combined EGR3.
SNP Chr Hg18 Position A1 A2 MAF Controls MAF Cases GMAF P-value OR [95% CI]
rs1877670 8 22,546,561 C T 39.7% 44.1% 44.3% 0.1405 1.200 [0.940–1.530]
rs1996147 8 22,544,158 G A 34.0% 30.1% 41.2% 0.1748 0.840 [0.0650–1.080]
571 cases, 200 controls; 490 males, 281 females.
doi:10.1371/journal.pone.0135076.t007
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To date, three case-control and one family-based study have identified significant associa-
tions between SNPs in EGR3 and schizophrenia [11–13, 41]. An additional family study
revealed nominally significant transmission disequilibrium for EGR3 [11]. All of these studies
were in Asian populations, including Korean, Japanese, and CH. In all three case-control stud-
ies the same SNP, rs35201266, demonstrated association with schizophrenia [11–13]. In the
CH family study rs1996147 and rs3750192 showed association with schizophrenia, as did the
haplotype rs3750192-rs35201266 [41]. Other case-control studies in the Japanese and CH pop-
ulations failed to identify significant associations between SNPs in EGR3 and schizophrenia
[46–48], though only one of these three studies included rs35201266 [46].
EGR3 SNP rs35201266 has also been associated with prefrontal hemodynamic response to a
verbal fluency test in both control and schizophrenia subjects of Japanese ethnicity, suggesting
a relationship between EGR3 and cognitive function in a brain region implicated in schizophre-
nia [49]. rs35201266 resides in the single intron of EGR3, suggesting a possible functional role
in EGR3mRNA expression or post-transcriptional processing. In vitro analysis of this SNP
demonstrated a potential functional effect on transcription [11]. However, we did not genotype
rs35201266 in our samples as our NGS results demonstrated a ΔMAF of 4.3% in the EU group
and 3.2% in the AA group for this SNP, which did not meet our cut-off of scoring> 5% in at
least one group.
Only one study examining EGR3 associations in schizophrenia in a EU population has been
reported. Although that study, which focused on circadian rhythm-related genes, failed to
identify an association between SNPs in EGR3 and schizophrenia, it did report a suggestive
association between EGR3 and bipolar I disorder (p = 0.017), though this did not survive con-
trol for multiple comparisons [42]. Nominal associations were also found between two linked
EGR3 SNPs, rs10104039 and rs10095121, and child bipolar I disorder in a family based associa-
tion study of primarily EU participants (88% EU; p = 0.027 and p = 0.028) [43]. Numerous
findings, including reports from genome wide association studies (GWAS), indicating shared
genetic influences on both bipolar disorder and schizophrenia, highlight the potential relevance
of these findings for our study [50–52].
In addition to the genetics findings, post mortem studies have reported reduced EGR3
mRNA levels in schizophrenia patients’ brains [11, 14], and a biomedical informatics study
identified EGR3 as the central gene in a network of microRNAs and transcription factors
implicated in schizophrenia pathogenesis [53]. EGR3 also resides in a copy number variation
(CNV)-containing region of the chromosome [43], and CNVs have demonstrated a high corre-
lation with schizophrenia and other psychiatric illnesses [54].
The 8p chromosomal region, and indeed the specific location of EGR3 at 8p21.3, have been
repeatedly associated with schizophrenia susceptibility, specifically in the AA population [55–
58]. The importance of this region in schizophrenia is also supported by meta- analysis of 32
GenomeWide Linkage studies [59] and rank-based genome scan meta-analysis from 20
schizophrenia genome scans [60]. Although our study did not demonstrate association
between schizophrenia and EGR3 SNPs rs1877670 or rs1996147 in the AA cohort, the limited
number of available AA DNA samples led to the study being insufficiently powered to detect
Table 8. ARC SNP Association Analysis in All Populations Combined. All Samples Combined ARC.
SNP Chr Hg18 Position A1 A2 MAF Controls MAF Cases GMAF P-value OR [95% CI]
rs35900184 8 143,693,411 T C 19.5% 27.2% 26.5% 2.353e-07 1.540 [1.310–1.820]
1062 cases, 691 controls; 1015 males, 735 females.
doi:10.1371/journal.pone.0135076.t008
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variations of low effect size. Interestingly, rates of schizophrenia have been reported to be up to
three times higher in AA than EU individuals, which may be due to differences in both genetic
and environmental causes [61].
The major limitation of our study was the number of samples available, particularly in the
AA group. Because of this, the DNA samples used for the discovery NGS study were included
in the validation phase. This was done for two reasons. First, the initial discovery phase used a
pooling approach that allowed us to cost-effectively sequence the region with a very high copy
number (providing a high level of accuracy), but did not discern individual genotype results
(only an average for the pool). Follow-up genotyping was therefore necessary to conduct asso-
ciation analyses. Second, the number of additional available samples was insufficient to power
an independent study. Inclusion of the original discovery set of DNAs in the genotype analysis
allowed us to increase our number of samples, which was still of a size that limited the power of
the study.
Lastly, it is important to note that the identified variants do not immediately suggest any
potential biological function; therefore, it is possible that they are closely linked with neighbor-
ing variants that may influence function of the underlying proteins. For example, rs1877670
falls within the 3’ UTR of EGR3, but doesn’t overlap with any known regulatory regions in the
gene, rs1996147 is located ~143kb downstream of EGR3 in the current build of the human
genome (GRCh37), and rs35900184 falls within an intron between exons 2 and 3 of ARC and
doesn’t overlap any known regulatory regions. Therefore the putative functional role of these
variants is in need of additional investigation.
Conclusions
We report that the EGR3 SNP rs1877670 is associated with schizophrenia in an EU population.
In addition, the ARC SNP rs1877670 shows association in both the EU and AA populations,
and is highly significant in a combined group of EU, AA, and CH populations. These findings
support our hypothesis that dysfunction of genes in the biological pathway of NMDA-recep-
tors to EGR3 regulation of ARCmay increase schizophrenia susceptibility. This pathway repre-
sents a molecular link between environment and the post-synaptic density proteins recently
implicated in schizophrenia risk by CNV and GWAS studies [28–30], and may provide insight
into the cognitive deficits characteristic of this illness.
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